Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Pharma Limited, a wholly-owned subsidiary of Biocon, has received U.S. FDA approval for its ANDA for Liraglutide Injection (generic Victoza), 18 mg/3 mL prefilled pens, used to treat Type 2 Diabetes in adults and children aged 10+. This is the second Liraglutide approval for the company in recent weeks, following the approval for generic Saxenda on February 24, 2026. Liraglutide is a complex GLP-1 class drug, and the approval strengthens Biocon's portfolio of complex generic products for the U.S. market. Victoza is a blockbuster product originally developed by Novo Nordisk, and generic entry typically opens a sizeable revenue opportunity for approved manufacturers.
Positive for shareholders — the U.S. FDA nod allows Biocon Pharma to launch a generic version of a high-value diabetes drug in the lucrative U.S. market, which could translate into meaningful new revenue. Back-to-back Liraglutide approvals signal strengthening execution in complex generics and may support long-term growth visibility.